These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 20619488)

  • 1. Revisiting nephrogenic systemic fibrosis in 6 kidney transplant recipients: a single-center experience.
    Lemy AA; del Marmol V; Kolivras A; High WA; Matos C; Laporte M; Nortier JL
    J Am Acad Dermatol; 2010 Sep; 63(3):389-99. PubMed ID: 20619488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Large sample of nephrogenic systemic fibrosis cases from a single institution.
    Lee CU; Wood CM; Hesley GK; Leung N; Bridges MD; Lund JT; Lee PU; Pittelkow MR
    Arch Dermatol; 2009 Oct; 145(10):1095-102. PubMed ID: 19841395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nephrogenic systemic fibrosis: clinical spectrum of disease.
    Mayr M; Burkhalter F; Bongartz G
    J Magn Reson Imaging; 2009 Dec; 30(6):1289-97. PubMed ID: 19937929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrospective assessment of prevalence of nephrogenic systemic fibrosis (NSF) after implementation of a new guideline for the use of gadobenate dimeglumine as a sole contrast agent for magnetic resonance examination in renally impaired patients.
    Abujudeh HH; Rolls H; Kaewlai R; Agarwal S; Gebreananya ZA; Saini S; Schaefer PW; Kay J
    J Magn Reson Imaging; 2009 Dec; 30(6):1335-40. PubMed ID: 19937927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ten-year experience with nephrogenic systemic fibrosis: case-control analysis of risk factors.
    Bahrami S; Raman SS; Sauk S; Salehmoghaddam S; Villablanca JP; Finn JP; Lu DS
    J Comput Assist Tomogr; 2009; 33(6):819-23. PubMed ID: 19940643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transmetallation and gadolinium: do low iron stores prevent the development of nephrogenic systemic fibrosis in high-risk end-stage renal disease patients?
    Panesar M; Boateng F; Patel SS; Masood SF; Mahajan P; Patel N; Murray B
    Hemodial Int; 2010 Jul; 14(3):289-94. PubMed ID: 20662951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue.
    Wiginton CD; Kelly B; Oto A; Jesse M; Aristimuno P; Ernst R; Chaljub G
    AJR Am J Roentgenol; 2008 Apr; 190(4):1060-8. PubMed ID: 18356456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nephrogenic systemic fibrosis in advanced chronic kidney disease: a single hospital's experience in Taiwan.
    Chen W; Huang SL; Huang CS; Tsai MC; Lai HM; Lui CC; Eng HL; Chang HW; Lee CH; Chuang FR
    Eur J Dermatol; 2009; 19(1):44-9. PubMed ID: 19059824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiorgan gadolinium (Gd) deposition and fibrosis in a patient with nephrogenic systemic fibrosis--an autopsy-based review.
    Sanyal S; Marckmann P; Scherer S; Abraham JL
    Nephrol Dial Transplant; 2011 Nov; 26(11):3616-26. PubMed ID: 21441397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nephrogenic systemic fibrosis, in patients with end-stage kidney disease on dialysis, in the greater Auckland region, from 2000-2006.
    Kendrick-Jones JC; Voss DM; De Zoysa JR
    Nephrology (Carlton); 2011 Feb; 16(2):243-8. PubMed ID: 21272139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nephrogenic systemic fibrosis and gadolinium-based contrast agents.
    Abu-Alfa AK
    Adv Chronic Kidney Dis; 2011 May; 18(3):188-98. PubMed ID: 21531325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of NSF following intravenous gadolinium-contrast media administration in dialysis patients with endstage renal disease.
    Heinz-Peer G; Neruda A; Watschinger B; Vychytil A; Geusau A; Haumer M; Weber M
    Eur J Radiol; 2010 Oct; 76(1):129-34. PubMed ID: 19619969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nephrogenic systemic fibrosis and management of high-risk patients.
    Altun E; Semelka RC; Cakit C
    Acad Radiol; 2009 Jul; 16(7):897-905. PubMed ID: 19375360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The debate between gadolinium versus erythropoietin in a renal transplant patient with nephrogenic systemic fibrosis.
    Hashemi P; Sina B; Rietkerk W; Safai B
    J Nephrol; 2013; 26(1):48-54. PubMed ID: 22573525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. UV-A1 therapy for nephrogenic systemic fibrosis.
    Tran KT; Prather HB; Cockerell CJ; Jacobe H
    Arch Dermatol; 2009 Oct; 145(10):1170-4. PubMed ID: 19841406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting.
    Broome DR
    Eur J Radiol; 2008 May; 66(2):230-4. PubMed ID: 18372138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nephrogenic systemic fibrosis: report of an additional case with granulomatous inflammation.
    Wilford C; Fine JD; Boyd AS; Sanyal S; Abraham JL; Kantrow SM
    Am J Dermatopathol; 2010 Feb; 32(1):71-5. PubMed ID: 19940755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nephrogenic systemic fibrosis.
    Weinreb JC; Kuo PH
    Magn Reson Imaging Clin N Am; 2009 Feb; 17(1):159-67. PubMed ID: 19364606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nephrogenic systemic fibrosis: pathogenesis, diagnosis, and therapy.
    Kribben A; Witzke O; Hillen U; Barkhausen J; Daul AE; Erbel R
    J Am Coll Cardiol; 2009 May; 53(18):1621-8. PubMed ID: 19406336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tissue gadolinium deposition and fibrosis mimicking nephrogenic systemic fibrosis (NSF)-subclinical nephrogenic systemic fibrosis?
    Boyd AS; Sanyal S; Abraham JL
    J Am Acad Dermatol; 2010 Feb; 62(2):337-42. PubMed ID: 19939504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.